Related Experiment Video

Updated: Jul 29, 2026

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
08:05

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

Lipid formulations of amphotericin B

S P Dix1, V T Andriole

  • 1Saint Luke's Hospital of Kansas City, Missouri, USA.

Current Clinical Topics in Infectious Diseases
|August 16, 2000
PubMed

Insights

Systemic fungal infections are rising, particularly in immunocompromised individuals. Lipid formulations of amphotericin B offer an important therapeutic option for invasive fungal infections, despite conventional amphotericin B toxicity.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Increasing incidence of systemic fungal infections, especially in immunocompromised patients.
  • Conventional amphotericin B is standard but toxic.
  • Three lipid formulations of amphotericin B are now approved in the US.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical experience, toxicity, dosing, and cost of three lipid formulations of amphotericin B.
  • To assess the role of these lipid formulations in managing invasive fungal infections.

Main Methods:

  • Review of existing literature and clinical data on lipid formulations of amphotericin B.
  • Detailed analysis of pharmacology, pharmacokinetics, clinical efficacy, safety profiles, dosing strategies, and cost-effectiveness.

Main Results:

  • Lipid formulations of amphotericin B (lipid complex, colloidal dispersion, liposomal) have distinct pharmacological and pharmacokinetic profiles.
  • Clinical data suggest comparable or improved efficacy with reduced toxicity compared to conventional amphotericin B for certain infections.
  • Dosing strategies and cost vary among the formulations, impacting clinical decision-making.

Conclusions:

  • Lipid formulations of amphotericin B are crucial therapeutic options for invasive fungal infections.
  • These formulations offer an improved safety profile, particularly for high-risk patient populations.
  • Further comparative studies may refine optimal use and cost-effectiveness in clinical practice.

More Related Videos

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

Formulation and Characterization of Bioactive Agent Containing Nanodisks07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Related Concept Videos

Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...